Prof. Isabelle Ray-Coquard (Université Claude Bernard, Lyon, France) presented the late-breaking results of the PAOLA-1/ENGOT-ov25 trial showing a benefit in progression-free survival when adding the PARP inhibitor olaparib to bevacizumab treatment, in an all-comers ovarian cancer population, irrespective of BRCA mutation .
PAOLA-1/ENGOT-ov25 is the first phase 3 trial to examine the efficacy and safety of a pharmacological inhibitor of the enzyme poly-ADP ribose polymerase (PARP) with bevacizumab as first-line maintenance therapy in patients in women with newly-diagnosed advanced ovarian cancer who had a complete or partial response to first-line treatment with platinum-based chemotherapy and bevacizumab, with and without a BRCA mutation. This international, academic-led trial enrolled 806 patients. After completing first-line chemotherapy, patients were randomly allocated ...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« 25% reduction in the risk of death in patients with nmCRPC treated with apalutamide Next Article
Ceritinib in ALK+ NSCLC brain metastases »
Table of Contents: ESMO 2019
Solid tumours/pan-tumour data
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.